For the Inventor, By the Inventor

Enter assignee name

Nihon Medi-Physics Company, Limited

USPTO Granted Patents = 142

CIPO Patents = 8

EPO Patents = 35

Trademarks = 2

Forward Citations = 1,106

Loading Chart...

Loading Chart...

200 inventors (with patents filed for the assignee):

Nobuo Ueda (18 out of 19 patents)

Makoto Azuma (17 out of 17 patents)

Akio Hayashi (16 out of 48 patents)

4. Masahito Toyama (14 out of 14 patents)

5. Daisaku Nakamura (13 out of 13 patents)

6. Masaaki Hazue (13 out of 14 patents)

7. Akira Yokoyama (13 out of 14 patents)

8. Yuki Okumura (12 out of 13 patents)

9. Hirohiko Yamauchi (10 out of 10 patents)

10. Shigemi Seri (10 out of 10 patents)

11. Fumie Kurosaki (9 out of 9 patents)

12. Ikuya Seki (9 out of 9 patents)

13. Susumu Kondo (9 out of 9 patents)

14. Osamu Ito (8 out of 8 patents)

15. Toshiyuki Shinmura (8 out of 8 patents)

Core Competencies:

Radioactive Labeling

Radiopharmaceuticals

Diagnostic Imaging Agents

Neurodegenerative Disorders

Amyloid Affinity Compounds

Nuclear Medicine Analysis

SPECT Imaging

PET Imaging

Radiohalogen Compounds

Target Production Methods

Medical Imaging Techniques

Radiochemical Synthesis

142 patents: Sort by Forward Citations

1. 12179149 - Method for purifyingRa-containing solution, method for producingRa target, and method for producingAc (2024-12-31),

2. 12046385 - Production method of 226Ra target, production method of 225Ac, and electrodeposition solution for producing 226Ra target (2024-07-23),

3. 11752223 - Method for producing Ac-225 solution and method for producing medicine using Ac-225 solution (2023-09-12),

4. 11701440 - Modified antibody and radioactive metal-labelled antibody (2023-07-18),

5. 11551826 - Method for producingAc (2023-01-10),

6. 11369701 - Ri-labeled humanized antibody (2022-06-28),

7. 11318216 - Method for producing radiohalogen-labeled compound and method for producing radiopharmaceutical (2022-05-03),

8. 11266753 - 2-[5-(imidazol-1-ylmethyl)pyridin-3-yl]benzimtdazole derivative compound, and medicament including same (2022-03-08),

9. 11083804 - Precursor compound of radioactive halogen-labeled organic compound (2021-08-10),

10. 10953112 - Precursor compound of radioactive halogen-labeled organic compound (2021-03-23),

11. 10857245 - Diagnostic imaging agent for early bone metastasis from cancer (2020-12-08),

12. 10703726 - Method for producing radiopharmaceutical composition (2020-07-07),

13. 10472338 - Method for producing [F]flutemetamol (2019-11-12),

14. 10395364 - Nuclear medical image analysis technique (2019-08-27),

15. 10366479 - Technique for normalizing scintigraphy image (2019-07-30),

Nihon Medi-Physics Company, Limited is a leading provider of diagnostic imaging agents and radiopharmaceutical products. With a strong focus on research and development, they strive to contribute to the advancement of medical diagnostic technologies. Nihon Medi-Physics offers a wide range of innovative products, including PET radiopharmaceuticals, SPECT radiotracers, and contrast agents for MRI and CT scans. They are committed to ensuring the highest standards of safety and quality in their products, aiming to improve patient care and outcomes. Visit their website for more information.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

142 Patents

#384 in Tokyo

#866 in Japan

#5,580 in the World

Nihon Medi-Physics Company, Limited

Forward Citations = 1,106

200 inventors:

Nobuo Ueda (18 out of 19 patents)

Makoto Azuma (17 out of 17 patents)

Akio Hayashi (16 out of 48 patents)

4. Masahito Toyama (14 out of 14 patents)

5. Daisaku Nakamura (13 out of 13 patents)

Please report any incorrect information to support@idiyas.com

Loading…